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Editorial on the Research Topic
ADAM, ADAMTS and Astacin Proteases: Challenges and Breakthroughs in the -Omics Era
Metzincins are a superfamily of metalloproteinases characterized by the presence of a conserved
methionine residue downstream the active site zinc (Cerdà-Costa and Gomis-Rüth, 2014). This
Frontiers Research Topic is focused on three metzincin sub-families: ADAMs (A Disintegrin and
Metalloproteinases), ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs)
and Astacins. Research into these proteases has seen impressive breakthroughs thanks to the progress
of the -Omics era. Genome Wide Association Studies (GWAS) have implicated several ADAM and
ADAMTS family members in human disease, for example ADAMTS7 in Coronary Artery Disease
(Reilly et al., 2011), and ADAM10 in Alzheimer’s disease (Marioni et al., 2018; Schwartzentruber
et al., 2021). Although less characterized, the proteolytic activity of Astacins has been linked to
digestion, cytokine activation and cancer (Sterchi et al., 2008; Peters and Becker-Pauly, 2019).
ADAMTSs are a family of 19 secreted proteases playing a crucial role in the turnover of the
extracellular matrix (ECM). While a fine regulation of their activity ensures tissue homeostasis,
several pathological conditions are associated with their aberrant activity. Rose et al. comprehensively
review the current knowledge about regulatory mechanisms of ADAMTS activity. Protein levels and
activity of ADAMTSs can be modulated at different levels, including transcriptional regulation,
alternative splicing, proteolytic activation, endocytosis, and inhibition by tissue inhibitors of
metalloproteinases (TIMPs). A deeper understanding of such regulatory mechanisms can lead to
new strategies to target the pathological potential of specific ADAMTSs without affecting the
physiological activity of other family members. The contribution by Jiang et al. provides updated
insights on multiple layers of regulation of one of the best characterized ADAMTS family members,
ADAMTS5. ADAMTS5 is an important pharmaceutical target in osteoarthritis (OA) due to its ability
to cleave aggrecan, the major proteoglycan in articular cartilage (Santamaria, 2020). Since no disease-
modifying OA therapies are currently available, the authors summarize current preclinical
approaches to target ADAMTS5. Monoclonal antibodies and small molecule inhibitors against
ADAMTS5 were proved to be beneficial pre-clinically. Based on the recent novel RNA therapies that
demonstrated potential in OA animal models, the authors emphasize that upstream signaling
blockade of ADAMTS5 using mi/siRNAs may represent a feasible therapeutic strategy for OA.
ADAMTS12 is another example of how we are just starting to scratch the surface of ADAMTS
complexity. Mohamedi et al. overview this complex and multifunctional metalloproteinase on the
Edited and reviewed by:
Andrea Mozzarelli,





This article was submitted to
Protein Chemistry and Enzymology,
a section of the journal
Frontiers in Molecular Biosciences
Received: 20 September 2021
Accepted: 23 September 2021
Published: 12 October 2021
Citation:
Yamamoto K, de Groot R, Scilabra SD,
Kwok HF and Santamaria S (2021)
Editorial: ADAM, ADAMTS and Astacin
Proteases: Challenges and
Breakthroughs in the -Omics Era.
Front. Mol. Biosci. 8:780242.
doi: 10.3389/fmolb.2021.780242
Frontiers in Molecular Biosciences | www.frontiersin.org October 2021 | Volume 8 | Article 7802421
EDITORIAL
published: 12 October 2021
doi: 10.3389/fmolb.2021.780242
20th anniversary of its identification. The authors discuss
functions of ADAMTS12 in inflammatory processes, arthritis,
degenerative intervertebral disc, chondrogenesis, tendon
degeneration, cancer, neurological and fertility disorders.
Different domains of ADAMTS12 can interact with different
ECM components, which in turn modify its proteolytic activity.
The authors emphasize that identification of ADAMTS12-binding
partners would contribute to a deeper understanding of its
biological functions.
A central aspect of this Research Topic is the identification of
novel metzincin substrates using state-of-the-art proteomics
approach. In the last decade, mass spectrometry-based
techniques have dramatically expanded our knowledge of
proteases’ substrate repertoire, the degradome (López-Otín and
Overall, 2002). The most successful techniques have been those
targeting the newly formed N-terminus generated following
cleavage of the substrate, such as N-Terminal Amine Isotopic
Labeling of Substrates (TAILS) (Mintoo et al., 2021). N-TAILS
has been instrumental to elucidate the degradome of ADAMTS7
(Colige et al., 2019), 2, 3, and 14 (Bekhouche et al., 2016). While
these approaches used fibroblast conditioned media as a source of
substrates, Leduc et al. investigated substrates in vivo by directly
comparing skin from Adamt2−/−, Adamts14−/− and Adamts2−/−/
Adamts14−/− knockout mice with those of wild type littermates.
Their results confirm the cleavage site preference (P1 and P1′
residues) of these proteases and provide more detail about their
role in collagen fibril organization. As often in proteomics,
further studies are required to assess the relevance of these
intriguing proteolytic events and novel substrates.
The current pandemic has stressed the need for better
intervention strategies aiming at the prevention and treatment
of infections caused by respiratory viruses. As highlighted by
Pedrina and Stambas, the ECM offers novel opportunities for
intervention. The proteoglycan versican is a major ECM
component and has been shown to be involved in the immune
response to viral infection by binding chemokines that guide
leukocyte extravasation. Versican also provides a barrier for
leukocyte migration, as summarized in the contribution by
McMahon et al. ADAMTS4 and ADAMTS5 are the two major
versicanases (Santamaria et al., 2019), so it does not come as a
surprise that they have been implicated in the pathological ECM
remodeling that occurs upon viral infection. However, their role
seems to be radically different. ADAMTS5 versicanase activity
seems to exert a beneficial role by facilitating leucocyte migration
as demonstrated by the delayed virus clearance observed in
Adamts5 knockout mice (McMahon et al., 2016). On the other
hand, ADAMTS4 expression positively correlates with severe
influenza virus infection in humans (Boyd et al., 2020),
suggesting that ADAMTS4 can be a potential target for
therapeutic intervention. Several inhibitory antibodies have
been described (Santamaria and de Groot, 2019) and these can
be deployed to target ADAMTS4 and other metzincins involved
in the dysregulated immune response to viral infection. On the
other hand, increasing the activity of ADAMTS5 in the context of
severe influenza infection may not be trivial. Although increased
ADAMTS5 activity has been achieved indirectly by blocking its
endocytosis with amonoclonal antibody (Santamaria et al., 2017),
a caveat when considering ADAMTSs as therapeutic targets is
their complex, multisystemic role, for example their involvement
in cardiovascular homeostasis (Santamaria and de Groot, 2020).
Like ADAMs, Astacins can cleave membrane-tethered
proteins and therefore act as sheddases (Sterchi et al., 2008;
Peters and Becker-Pauly, 2019). Meprin β is perhaps the best
characterized Astacin. Meprin β is a type I transmembrane
protein whose expression is associated with certain types of
cancer, including melanoma. Thus, it is crucial to find the
driver mutation(s) of meprin β and its variants to study the
impact on the invasiveness of tumor cells. Two genetic variants of
meprin β (G45R and G89R) have been found in melanomas.
Gellrich et al. characterized these two variants and found that,
similar to wild type meprin β, the G45R variant is able to shed a
number of specific substrates and promote invasion when
expressed in HeLa cancer cells. On the other hand, the G89R
variant showed impaired trafficking to the cell surface, reduced
shedding of its target substrates and diminished cancer cell
invasion. A similar mechanistic approach can be extended to
elucidate the activity of other meprin β variants (Peters and
Becker-Pauly, 2019).
Overall, the studies included in this Research Topic expand
our knowledge of the role and regulation of ADAMs, ADAMTSs
and Astacins in a variety of biological processes, something that
would not have been possible without the powerful new -Omics
tools that have been widely adopted in the last decade.
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